HealthDay.com
AHA: Tirzepatide Beneficial for Heart Failure With Preserved EF, Obesity
Lower risk for composite of death from cardiovascular causes or worsening heart failure seen with tirzepatide versus placebo
Recovery From Anti-NMDAR Encephalitis Continues for Three Years
34 percent of patients have persistent impairment beyond 36 months, although most have favorable outcome on mRS
Entinostat + Nivolumab Yields Durable Results in Some Pancreatic Cancer Patients
Primary end point not met, but small subset of advanced pancreatic ductal adenocarcinoma patients showed durable responses
AHA: Initial Catheter Ablation Beneficial for Ventricular Tachycardia
Initial strategy of catheter ablation leads to lower risk for composite primary end point versus antiarrhythmic drug therapy
Considerable Disparities in Life Expectancy Exist Within U.S. Population
Large disparities in life expectancy observed, which grew over time, especially during the first two years of COVID-19
Semaglutide, Liraglutide May Reduce Hospitalization Risk for Alcohol Use Disorder
Semaglutide and liraglutide also linked to reduction in risks for SUD hospitalization, somatic hospitalizations
Estimated 100,429 U.S. Youth Living With Pediatric Inflammatory Bowel Disease
Prevalence of Crohn disease higher in males; variation seen in prevalence by race and ethnicity
Younger Patients More Affected by Neurologic Manifestations of Long COVID
Younger and middle-aged patients have higher burden of neurologic symptoms, fatigue, sleep disturbance, cognitive dysfunction
E. Coli Fears Spur Recall of 167,000 Pounds of Ground Beef
24.3 Percent of U.S. Adults Had Chronic Pain in Past Three Months in 2023
Chronic pain, high-impact chronic pain prevalence increased with age; American Indian and Alaska Native non-Hispanic adults more likely to have chronic pain
